Background: Current antiretroviral therapy (ART) cannot cure HIV-1
infection due to the presence of latent viral reservoirs. The “shock and kill” strategy
is a promising approach to eliminate the viral reservoir. However, there are various
limits existing in current latency-reversing agents, searching for new activators
are urgently needed.
Objective: The present study aimed at investigating the ability of hymecromone
and scoparone for activating HIV-1 from latent reservoirs.
Methods: Jurkat T cell model of HIV-1 latently were used to evaluate the effect of
hymecromone and scoparone. The percentage of green florescence protein expression
as a marker for reactivation of HIV-1 promoter was measured via FACScan.
The expression of CD25 and CD69 in human peripheral blood mononuclear cells was measured by
flow cytometry at 72 h post-treatment with hymecromone or scoparone or prostratin using antibodies
against CD25 and CD69.
Results: Hymecromone and scoparone can induce HIV-1 LTR reactivation in a dose and timedependent.
We further show that hymecromone and scoparone can reactivate latent virus without inducing
the activation of global T cells. We also found that scoparone acts by NF-&kgr;B signal pathway.
Conclusion: Hymecromone and scoparone can effectively reactivate latent HIV-1 with low cellular
toxicity, indicating hymecromone and scoparone might be potential drugs for HIV-1 reservoir eradication
strategies in the future.